Literature DB >> 1888626

Mefloquine pharmacokinetics and resistance in children with acute falciparum malaria.

F Nosten1, F ter Kuile, T Chongsuphajaisiddhi, K Na Bangchang, J Karbwang, N J White.   

Abstract

The pharmacokinetic properties of mefloquine hydrochloride (15 mg base kg -1) were studied in 12 Karen children (five girls, seven boys) aged between 5 and 10 years presenting with uncomplicated falciparum malaria. The drug was well tolerated. Mean (s.d.) peak blood drug concentrations of 2031 (831) ng ml-1 were reached in a median of 8 (range 6-24) h. Mean (s.d.) estimates for oral clearance and mean residence time were 0.52 (0.27) ml min -1 kg -1 and 15.3 (4.7) days, respectively. These values are similar to those reported previously in adults. In one child parasitaemia failed to clear despite whole blood mefloquine concentrations which peaked at 1744 ng ml -1; parasitaemia rose and fever recurred when blood drug concentrations had fallen to 442 ng ml -1. The prevalence of highly mefloquine resistant parasites such as this can be expected to increase under drug pressure in this area.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1888626      PMCID: PMC1368477          DOI: 10.1111/j.1365-2125.1991.tb05581.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  Mefloquine disposition in normals and in patients with severe Plasmodium falciparum malaria.

Authors:  F D Juma; J O Ogeto
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Jan-Mar       Impact factor: 2.441

2.  Response of Plasmodium falciparum to chloroquine treatment: relation to whole blood concentrations of chloroquine and desethylchloroquine.

Authors:  U Hellgren; C M Kihamia; L F Mahikwano; A Björkman; O Eriksson; L Rombo
Journal:  Bull World Health Organ       Date:  1989       Impact factor: 9.408

3.  A comparison of the pharmacokinetics of mefloquine in healthy Thai volunteers and in Thai patients with falciparum malaria.

Authors:  J Karbwang; D J Back; D Bunnag; A M Breckenridge
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Malaria on the Thai-Burmese border: treatment of 5192 patients with mefloquine-sulfadoxine-pyrimethamine.

Authors:  F Nosten; S Imvithaya; M Vincenti; G Delmas; G Lebihan; B Hausler; N White
Journal:  Bull World Health Organ       Date:  1987       Impact factor: 9.408

Review 5.  Clinical pharmacokinetics of mefloquine.

Authors:  J Karbwang; N J White
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of antimalarial drugs.

Authors:  N J White
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

7.  Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine.

Authors:  J Karbwang; S Looareesuwan; R E Phillips; Y Wattanagoon; M E Molyneux; B Nagachinta; D J Back; D A Warrell
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

8.  Serum quinine concentrations following the initial dose in children with falciparum malaria.

Authors:  A Sabchareon; T Chongsuphajaisiddhi; P Attanath
Journal:  Southeast Asian J Trop Med Public Health       Date:  1982-12       Impact factor: 0.267

9.  Intragastric mefloquine is absorbed rapidly in patients with cerebral malaria.

Authors:  P Chanthavanich; S Looareesuwan; N J White; D A Warrell; M J Warrell; J H DiGiovanni; J von Bredow
Journal:  Am J Trop Med Hyg       Date:  1985-11       Impact factor: 2.345

Review 10.  Treatment of malaria: some considerations and limitations of the current methods of assessment.

Authors:  N J White; S Krishna
Journal:  Trans R Soc Trop Med Hyg       Date:  1989 Nov-Dec       Impact factor: 2.184

View more
  12 in total

1.  The influence of body weight on the pharmacokinetics of mefloquine.

Authors:  J A SImpson; L Aarons; R Price; N J White
Journal:  Br J Clin Pharmacol       Date:  2002-03       Impact factor: 4.335

Review 2.  Antimalarial pharmacokinetics and treatment regimens.

Authors:  N J White
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

3.  Development of a physiologically based pharmacokinetic model for mefloquine and its application alongside a clinical effectiveness model to select an optimal dose for prevention of malaria in young Caucasian children.

Authors:  Trevor N Johnson; Yumi Cleary; Neil Parrott; Bruno Reigner; James R Smith; Stephen Toovey
Journal:  Br J Clin Pharmacol       Date:  2018-11-05       Impact factor: 4.335

4.  Population pharmacokinetics of mefloquine in military personnel for prophylaxis against malaria infection during field deployment.

Authors:  B G Charles; A Blomgren; P E Nasveld; S J Kitchener; A Jensen; R M Gregory; B Robertson; I E Harris; M P Reid; M D Edstein
Journal:  Eur J Clin Pharmacol       Date:  2007-01-11       Impact factor: 2.953

5.  Susceptibility of Plasmodium falciparum strains to mefloquine in an urban area in Senegal.

Authors:  I Hatin; J F Trape; F Legros; J Bauchet; J Le Bras
Journal:  Bull World Health Organ       Date:  1992       Impact factor: 9.408

Review 6.  Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  K J Palmer; S M Holliday; R N Brogden
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

Review 7.  Pharmacokinetic profile of artemisinin derivatives and companion drugs used in artemisinin-based combination therapies for the treatment of Plasmodium falciparum malaria in children.

Authors:  Shane A Pawluk; Kyle J Wilby; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2013-03       Impact factor: 6.447

Review 8.  Halofantrine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic potential.

Authors:  H M Bryson; K L Goa
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

Review 9.  Use of mefloquine in children - a review of dosage, pharmacokinetics and tolerability data.

Authors:  Patricia Schlagenhauf; Miriam Adamcova; Loredana Regep; Martin T Schaerer; Sudhir Bansod; Hans-Georg Rhein
Journal:  Malar J       Date:  2011-10-07       Impact factor: 2.979

10.  The neurological assessment in young children treated with artesunate monotherapy or artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria.

Authors:  Michael T Ambler; Lilly M Dubowitz; Ratree Arunjerdja; Eh Paw Hla; Kyaw Lay Thwai; Jacher Viladpainguen; Pratap Singhasivanon; Christine Luxemburger; François Nosten; Rose McGready
Journal:  Malar J       Date:  2009-09-02       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.